Comparison of genotypic and phenotypic hIV type 1 tropism assay: Results from the screening samples of cenicriviroc study 202, a randomized phase II trial in treatment-naive subjects

AIDS Research and Human Retroviruses

Volumn 30, Issue 2, 2014, Pages 151-159

  Kagan, Ron M ^a   Johnson, Erik P ^a   Siaw, Martin F ^a   Van Baelen, Ben ^b   Ogden, Richard ^c   Platt, Jamie L ^a   Pesano, Rick L ^a   Lefebvre, Eric ^c  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b BVB CLIN Consult BVBA ^*  (Belgium)

^c Tobira Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENICRIVIROC; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASSAY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENHANCED SENSITIVITY TROFILE ASSAY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TROPISM; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, HIV; VIRAL TROPISM; VIROLOGY; YOUNG ADULT;

EID: 84893502384     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0123     Document Type: Article

References (57)

1. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
2. Goodenow MM and Collman RG: HIV-1 coreceptor preference is distinct from target cell tropism: A dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol 2006;80(5):965-972.
3. Ray N and Doms RW: HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 2006;303:97-120.
4. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185(4):621-628.
5. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, et al.: Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-Tropic HIV from the plasma of drug-naive individuals. AIDS 2008;22(12):1425-1431.
6. Shankarappa R, Margolick JB, Gange SJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73(12):10489-10502.
7. Poveda E, Briz V, de Mendoza C, et al.: Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007;79(8):1040-1046.
8. Brumme ZL, Goodrich J, Mayer HB, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192(3):466-474.
9. Chalmet K, Dauwe K, Foquet L, et al.: Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: Correlates and evidence for transmission. J Infect Dis 2012;205(2):174-184.
10. Moyle GJ, Wildfire A, Mandalia S, et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191(6):866-872.
11. Daar ES, Kesler KL, Petropoulos CJ, et al.: Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007;45(5):643-649.
12. Weiser B, Philpott S, Klimkait T, et al.: HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008;22(4):469-479.
13. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-4732.
14. Cooper DA, Heera J, Goodrich J, et al.: Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-Tropic HIV-1 infection. J Infect Dis 2010;201(6):803-813.
15. Fatkenheuer G, Nelson M, Lazzarin A, et al.: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359(14):1442-1455.
16. Gulick RM, Lalezari J, Goodrich J, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359(14):1429-1441.
17. Saag M, Goodrich J, Fatkenheuer G, et al.: A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009;199(11):1638-1647.
18. Whitcomb JM, Huang W, Fransen S, et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51(2): 566-575.
19. Gulick RM, Su Z, Flexner C, et al.: Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196(2):304-312.
20. Suleiman J, Zingman BS, Diaz RS, et al.: Vicriviroc in combination therapy with an optimized regimen for treatmentexperienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010;201(4):590-599.
21. Wilkin TJ, Su Z, Krambrink A, et al.: Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2010;54(5):470-476.
22. Reeves JD, Coakley E, Petropoulos CJ, and Whitcomb JM: An enhanced-sensitivity Trofile-HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies. J Viral Entry 2009;3(3):94-102.
23. Wilkin TJ, Goetz MB, Leduc R, et al.: Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 2011;52(7):925-928.
24. Su Z, Gulick RM, Krambrink A, et al.: Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009;200(11): 1724-1728.
25. Harrigan PR and Geretti AM: Genotypic tropism testing: Evidence-based or leap of faith? AIDS 2011;25(2):257-264.
26. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253(5015):71-74.
27. McGovern RA, Thielen A, Mo T, et al.: Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010;24(16):2517-2525.
28. McGovern RA, Thielen A, Portsmouth S, et al.: Populationbased sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 2012;61(3):279-286.
29. Prosperi MC, Bracciale L, Fabbiani M, et al.: Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010;7:56.
30. Recordon-Pinson P, Soulie C, Flandre P, et al.: Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: The ANRS GenoTropism study. Antimicrob Agents Chemother 2010;54(8):3335-3340.
31. Symons J, Vandekerckhove L, Paredes R, et al.: Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. Clin Microbiol Infect 2012;18(6): 606-612.
32. Knapp DJ, McGovern RA, Dong W, et al.: Factors influencing the sensitivity and specificity of conventional sequencing in human immunodeficiency virus type 1 tropism testing. J Clin Microbiol 2013;51(2):444-451.
33. Margulies M, Egholm M, Altman WE, et al.: Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005;437(7057):376-380.
34. Archer J, Braverman MS, Taillon BE, et al.: Detection of lowfrequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009;23(10):1209-1218.
35. Daumer M, Kaiser R, Klein R, Lengauer T, Thiele B, and Thielen A: Genotypic tropism testing by massively parallel sequencing: Qualitative and quantitative analysis. BMC Med Inform Decis Mak 2011;11:30.
36. Swenson LC, Moores A, Low AJ, et al.: Improved detection of CXCR4-using HIV by V3 genotyping: Application of population-based and 'deep' sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010;54(5): 506-510.
37. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, and Shafer RW: Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res 2007;17(8):1195-1201.
38. Kagan RM, Johnson EP, Siaw M, et al.: A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One 2012;7(9):e46334.
39. Swenson LC, Mo T, Dong WW, et al.: Deep sequencing to infer HIV-1 co-receptor usage: Application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011;203(2):237-245.
40. Swenson LC, Mo T, Dong WW, et al.: Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: A reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011;53(7):732-742.
41. Klibanov OM, Williams SH, and Iler CA: Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 2010;11(8):940-950.
42. Lalezari J, Gathe J, Brinson C, et al.: Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonistnaive subjects. J Acquir Immune Defic Syndr 2011;57(2): 118-125.
43. Marier JF, Trinh M, Pheng LH, Palleja SM, and Martin DE: Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob Agents Chemother 2011;55(6):2768-2774.
44. McGovern RA, Harrigan PR, and Swenson LC: Genotypic inference of HIV-1 tropism using population-based sequencing of V3. J Visual Exp: JoVE 2010(46).
45. Woods CK, Brumme CJ, Liu TF, et al.: Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012;50(6):1936-1942.
46. Sing T, Low AJ, Beerenwinkel N, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007;12(7):1097-1106.
47. Jensen MA, Li FS, van 't Wout AB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-To-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77(24): 13376-13388.
48. Vandekerckhove LP, Wensing AM, Kaiser R, et al.: European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11(5):394-407.
49. Seclen E, Soriano V, Gonzalez MM, Gomez S, Thielen A, and Poveda E: High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol 2011;49(9):3380-3382.
50. Raymond S, Recordon-Pinson P, Saliou A, et al.: Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. J Antimicrob Chemother 2011;66(9): 1972-1975.
51. Portsmouth S, Valluri SR, Daumer M, et al.: Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naive HIV patients screened for Study A4001078. Antiviral Res 2013;97(1):60-65.
52. Buonaguro L, Tornesello ML, and Buonaguro FM: Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol 2007;81(19):10209-10219.
53. Raymond S, Delobel P, Mavigner M, et al.: Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 2010;53(2): 167-175.
54. Lee GQ, Harrigan PR, Dong W, et al.: Comparison of population and 454 'deep' sequence analysis for HIV-1 tropism versus the original Trofile assay in non-B subtypes. AIDS Res Hum Retroviruses 2013;29(6):979-984.
55. Raymond S, Delobel P, Chaix ML, et al.: Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011;8:56.
56. Raymond S, Delobel P, Mavigner M, et al.: Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009;47(7):2292-2294.
57. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed February 12, 2013.